Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104698 | 0.89 | PARP1 (0.55) | PARP14ENPP1TNKS2PARP1TNKS | |
| SCHEMBL19104685 | 0.84 | MAPT (0.47) | PARP14TNKS2PARP1KDM4ERECQL | |
| SCHEMBL17298079 | 0.84 | TNKS2 (0.62) | PARP14ENPP1TNKS2PARP1KDM4E | |
| SCHEMBL19116631 | 0.83 | ALDH1A1 (0.56) | TNKS2PARP1TNKSKDM4EALDH1A1 | |
| SCHEMBL19104694 | 0.83 | LMNA (0.54) | KDM4ERECQLALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19116440 | 0.81 | KDM4C (0.59) | PARP14ENPP1TNKS2PARP1KDM4E | |
| SCHEMBL29978378 | 0.81 | KDM4E (0.63) | PARP14ENPP1TNKS2PARP1KDM4E | |
| SCHEMBL21072570 | 0.81 | KDM4E (0.63) | PARP14ENPP1TNKS2PARP1KDM4E | |
| SCHEMBL19104682 | 0.79 | TNKS2 (0.69) | TNKS2PARP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30176853 | 0.79 | TNKS2 (0.69) | TNKS2PARP1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | PARP14 3642/4885ENPP1 2346/4885TNKS2 4481/4885 |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | PARP14 3642/4885ENPP1 2346/4885TNKS2 4481/4885 |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | PARP14 3642/4885ENPP1 2346/4885TNKS2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.